Menu
11/11/2003
Galen post better than expected full year figures
Northern Ireland based pharmaceuticals company Galen has posted better than expected end of year figures.
Total operating profit for the company was up 79% at US$187 million, from almost US$105 million in 2002, and sales revenue rose almost 46% to reach US$432 million in the year, up from US$296 million in 2002.
Revenue largely due to an aggressive portfolio expansion increased by 84% to US$432.4 million, 27% up on the corresponding period in the preceding year.
During the year, Galen committed US$650 million to acquiring products and rights, which increased margins giving a US$208 million in cash form operations. Galen ended the year with a US$253.3 million debt.
The Board recommended the payment of a final dividend of 2.4p per ordinary share, a total dividend for the year of 3.6p, which represented an increase of 20% on the previous year
The company is also looking forward to a favourable outcome from is purchase of Sarafem from Eli Lily in January this year, and three products purchased from Pfizer in April of this year.
Commenting on the results, Galen Chief Executive Roger Boissonneault said: "The past year established Galen’s pharmaceutical products business as the focus of the company. We have significantly strengthened our US presence through the execution of our growth strategy, to continue organic growth, new product development and selective acquisitions. Galen is well positioned to execute its growth strategy into '04' and beyond."
In morning trading Galen shares nudged 4% higher on the back of the company's favourable year-end figures.
(SP)
Total operating profit for the company was up 79% at US$187 million, from almost US$105 million in 2002, and sales revenue rose almost 46% to reach US$432 million in the year, up from US$296 million in 2002.
Revenue largely due to an aggressive portfolio expansion increased by 84% to US$432.4 million, 27% up on the corresponding period in the preceding year.
During the year, Galen committed US$650 million to acquiring products and rights, which increased margins giving a US$208 million in cash form operations. Galen ended the year with a US$253.3 million debt.
The Board recommended the payment of a final dividend of 2.4p per ordinary share, a total dividend for the year of 3.6p, which represented an increase of 20% on the previous year
The company is also looking forward to a favourable outcome from is purchase of Sarafem from Eli Lily in January this year, and three products purchased from Pfizer in April of this year.
Commenting on the results, Galen Chief Executive Roger Boissonneault said: "The past year established Galen’s pharmaceutical products business as the focus of the company. We have significantly strengthened our US presence through the execution of our growth strategy, to continue organic growth, new product development and selective acquisitions. Galen is well positioned to execute its growth strategy into '04' and beyond."
In morning trading Galen shares nudged 4% higher on the back of the company's favourable year-end figures.
(SP)
Related Northern Ireland News Stories
Click here for the latest headlines.
14 November 2002
US growth aids Galen profits gain
Improved growth in the United States has helped Craigavon-based, Galen Holdings post its strongest set of results since flotation in 1997. The pharmaceutical company revealed that profits rose to £101m from £41m over the past year while revenues for the past 12 months rose to £102m from last year's £187m.
US growth aids Galen profits gain
Improved growth in the United States has helped Craigavon-based, Galen Holdings post its strongest set of results since flotation in 1997. The pharmaceutical company revealed that profits rose to £101m from £41m over the past year while revenues for the past 12 months rose to £102m from last year's £187m.
14 November 2001
Galen report buoyant trading for year ending 2001
Galen Holdings, the international speciality pharmaceuticals company based in Craigavon, has posted buoyant profit figures. In the last trading year the company reported a turnover of £183 million for the year ended September 2001, up more than double on that of the previous year’s £86 million turnover figure.
Galen report buoyant trading for year ending 2001
Galen Holdings, the international speciality pharmaceuticals company based in Craigavon, has posted buoyant profit figures. In the last trading year the company reported a turnover of £183 million for the year ended September 2001, up more than double on that of the previous year’s £86 million turnover figure.
29 January 2003
£69m reallocated from departmental savings
NIO Trade Minister, Ian Pearson has today announced the re-distribution of millions of pounds of savings garnered from within departmental programmes in 2002-03. The Minister emphasised that this is not new money, but represents adjustments made within Northern Ireland’s own budget resources on the basis of need.
£69m reallocated from departmental savings
NIO Trade Minister, Ian Pearson has today announced the re-distribution of millions of pounds of savings garnered from within departmental programmes in 2002-03. The Minister emphasised that this is not new money, but represents adjustments made within Northern Ireland’s own budget resources on the basis of need.
12 March 2002
Extra £46m health funding still falls short
The Stormont Health minister Bairbre de Brún has said the extra £46 million being made available to tackle many of the major problems affecting the crisis-hit NHS is “not enough”. Ms de Brún, whose department received more than £2.
Extra £46m health funding still falls short
The Stormont Health minister Bairbre de Brún has said the extra £46 million being made available to tackle many of the major problems affecting the crisis-hit NHS is “not enough”. Ms de Brún, whose department received more than £2.
11 February 2004
Galen on course to double profits
NI-based pharmaceuticals company Galen has reported pre-tax profits of £26 million for the first quarter of the year, and is on course to double annual profits.
Galen on course to double profits
NI-based pharmaceuticals company Galen has reported pre-tax profits of £26 million for the first quarter of the year, and is on course to double annual profits.
-
Northern Ireland WeatherToday:A showery start with outbreaks most frequent north of Lough Neagh and through the morning, before dwindling during the afternoon as the northwest breezes ease and brighter spells of weak sunshine prosper. Maximum temperature 8 °C.Tonight:A dry night, save for a few light showers around the coasts, with prolonged clear spells and light winds bringing a frosty dawn for many in central and southern parts. Minimum temperature -3 °C.
